These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Defining tumor antigens: mRNA, protein or cytotoxicity? Lim SH; Periman P; Klug P; Weidanz J; Whitton V; Chiriva-Internati M; Wang Z; Wright S Trends Immunol; 2002 May; 23(5):236-7; author reply 237-8. PubMed ID: 12102740 [No Abstract] [Full Text] [Related]
3. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495 [No Abstract] [Full Text] [Related]
4. Genes coding for tumor-specific rejection antigens. Boon T; Van den Eynde B; Hirsch H; Moroni C; De Plaen E; van der Bruggen P; De Smet C; Lurquin C; Szikora JP; De Backer O Cold Spring Harb Symp Quant Biol; 1994; 59():617-22. PubMed ID: 7587121 [No Abstract] [Full Text] [Related]
5. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones. Maryanski JL; Boon T Eur J Immunol; 1982 May; 12(5):406-12. PubMed ID: 6178608 [TBL] [Abstract][Full Text] [Related]
6. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Maryanski JL; Van Snick J; Cerottini JC; Boon T Eur J Immunol; 1982 May; 12(5):401-6. PubMed ID: 6178607 [TBL] [Abstract][Full Text] [Related]
7. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815. Bilsborough J; Van Pel A; Uyttenhove C; Boon T; Van den Eynde BJ J Immunol; 1999 Mar; 162(6):3534-40. PubMed ID: 10092811 [TBL] [Abstract][Full Text] [Related]
8. Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity. Castelli M; Cianfriglia F; Manieri A; Palma L; Pezzuto RW; Falasca G; Delpino A Anticancer Res; 2001; 21(1B):753-8. PubMed ID: 11299839 [TBL] [Abstract][Full Text] [Related]
9. Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay. Wölfel T; Van Pel A; De Plaen E; Lurquin C; Maryanski JL; Boon T Immunogenetics; 1987; 26(3):178-87. PubMed ID: 3114137 [TBL] [Abstract][Full Text] [Related]
10. Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity. Goodell V; Disis ML J Immunol Methods; 2005 Apr; 299(1-2):129-38. PubMed ID: 15914197 [TBL] [Abstract][Full Text] [Related]
11. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Colmenero P; Liljeström P; Jondal M Gene Ther; 1999 Oct; 6(10):1728-33. PubMed ID: 10516722 [TBL] [Abstract][Full Text] [Related]
12. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. Uyttenhove C; Maryanski J; Boon T J Exp Med; 1983 Mar; 157(3):1040-52. PubMed ID: 6187879 [TBL] [Abstract][Full Text] [Related]
13. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. Van den Eynde B; Lethé B; Van Pel A; De Plaen E; Boon T J Exp Med; 1991 Jun; 173(6):1373-84. PubMed ID: 1903428 [TBL] [Abstract][Full Text] [Related]
14. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. De Plaen E; Lurquin C; Van Pel A; Mariamé B; Szikora JP; Wölfel T; Sibille C; Chomez P; Boon T Proc Natl Acad Sci U S A; 1988 Apr; 85(7):2274-8. PubMed ID: 3127830 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509 [TBL] [Abstract][Full Text] [Related]
16. Immune reactions of the syngeneic host after the intradermal injection of tumor cells and microsomes. Bertschmann M; Lüscher EF Adv Exp Med Biol; 1973; 29(0):513-8. PubMed ID: 4212066 [No Abstract] [Full Text] [Related]
17. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells. La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB J Immunol; 1998 Dec; 161(12):6552-8. PubMed ID: 9862681 [TBL] [Abstract][Full Text] [Related]
18. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. Arnold D; Faath S; Rammensee H; Schild H J Exp Med; 1995 Sep; 182(3):885-9. PubMed ID: 7650492 [TBL] [Abstract][Full Text] [Related]
19. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory. Dai J; Liu B; Caudill MM; Zheng H; Qiao Y; Podack ER; Li Z Cancer Immun; 2003 Jan; 3():1. PubMed ID: 12747743 [TBL] [Abstract][Full Text] [Related]
20. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H-2 associativity of variant-specific antigens. Van Snick J; Maryanski J; Van Pel A; Parmiani G; Boon T Eur J Immunol; 1982 Nov; 12(11):905-8. PubMed ID: 6818041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]